IAH0968

IAH0968 is a small-molecule drug developed by SUNHO（China）BioPharmaceutical CO.. Its target is HER2 (the sponsor names HER2). ClinicalTrials.gov describes the intervention as: Experimental：IAH0968 15 mg/kg on Day 1 of each 3-week cycle as an IV infusion. Drug: Oxaliplatin 130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen. Drug: Capecitabin. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06504732 (To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer), in gastric & gastro-oesophageal junction cancer. The largest, NCT06504732, plans to enrol 574 participants with primary completion expected 2028-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.